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Tumor necrosis factor receptor-associated factors
2 and 3 (TRAF2 and TRAF3) were shown to function
in a cooperative and nonredundant manner to sup-
press nuclear factor-kB2 (NF-kB2) activation, gene
expression, and survival in mature B cells. In the ab-
sence of this suppressive activity, B cells developed
independently of the obligatory B cell survival factor,
BAFF (B cell-activating factor of the tumor necrosis
factor family). However, deletion of either TRAF2
or TRAF3 from the T cell lineage did not promote
T cell survival, despite causing extensive NF-kB2
activation. This constitutive, lineage-specific sup-
pression of B cell survival by TRAF2 and TRAF3
determines the requirement for BAFF to sustain B
cell development in vivo. Binding of BAFF to BAFF
receptor reversed TRAF2-TRAF3-mediated suppres-
sion of B cell survival by triggering the depletion of
TRAF3 protein. This process was TRAF2 dependent,
revealing dual roles for TRAF2 in regulating B cell
homeostasis.
INTRODUCTION
Adaptive immunity depends on the production and maintenance
of a pool of mature peripheral B and T lymphocytes throughout
life. The expression of a functional antigen receptor is a prerequi-
site for the generation and subsequent survival of both of these
populations (Lam et al., 1997; Polic et al., 2001). However,
mature lymphocytes also require the delivery of antigen recep-
tor-independent signals from the extracellular milieu in order to
survive. The nature of these signals differs fundamentally be-
tween T and B cells. Thus, mature naive T cells require signals
delivered via the interleukin-7 receptor (Schluns et al., 2000;
Tan et al., 2001) whereas mature naive B cells depend on signals
delivered by B cell-activating factor of the tumor necrosis factor
family (BAFF = TNFSF13B). Mice that lack BAFF expression
(Tnfsf13b/) or that have undergone treatments designed to
block the action of BAFF fail to produce or maintain a matureB cell pool (Schiemann et al., 2001; Schneider et al., 2001;
Thompson et al., 2000). Three different members of the TNF
receptor (TNFR) superfamily act as receptors for BAFF, namely
BAFF-R (TNFRSF13C), TACI (TNFRSF13B), and BCMA
(TNFRSF17) (Mackay et al., 2007). Mature B cells express both
BAFF-R and TACI but require only BAFF-R to survive in vivo
(Sasaki et al., 2004; Shulga-Morskaya et al., 2004; von Bulow
et al., 2001; Yan et al., 2001).
Despite the essential role of the BAFF-BAFF-R signaling axis in
establishing and maintaining the peripheral B cell pool, the intra-
cellular events that link BAFF to its biological effects remain only
partially characterized. Unlike most members of the TNFR
superfamily, BAFF-R is a relatively weak inducer of acute re-
sponses such as the canonical nuclear factor-kB (NF-kB) and
the c-jun N-terminal kinase (JNK) pathways (Grech et al., 2004;
Morrison et al., 2005). In contrast, BAFF-R is a potent activator
of the kinetically slower alternative NF-kBpathway and is entirely
responsible for signaling the processing of the p100 NF-kB2
protein to its active p52 component in primary B cells (Claudio
et al., 2002; Kayagaki et al., 2002). Activation of the alternative
NF-kB pathway by BAFF is a major component of its biological
activity, because B cells lacking NF-kB2 or other critical
upstream activators of NF-kB2 processing, such as NF-kB-
inducing kinase (NIK) or I-kB kinase a (IKKa), display greatly
impaired survival and maturation in vivo (Kaisho et al., 2001;
Miosge et al., 2002; Senftleben et al., 2001; Yamada et al., 2000).
Members of the TNFR superfamily that lack cytoplasmic death
domains typically deliver intracellular signals by recruiting mem-
bers of the TNFR-associated factor (TRAF) family of signaling
proteins (Grech et al., 2000). Most non-death domain members
of the TNFR superfamily recruit multiple TRAFs to their cytoplas-
mic domains. BAFF-R, however, has only a single TRAF-binding
site that is specific for TRAF3 (Xu and Shu, 2002). Unlike TRAFs
2, 5, and 6, TRAF3 does not activate the canonical NF-kB or JNK
pathways when it is overexpressed or recruited to members of
the TNFR superfamily (Morrison et al., 2005; Rothe et al., 1995;
Song et al., 1997). Instead, TRAF3 appears to play a negative
regulatory role, particularly within the alternative NF-kB pathway
(Hauer et al., 2005; He et al., 2006). In vitro studies using a trans-
formed B cell line have shown that TRAF3 suppresses the
alternative NF-kB pathway by binding NIK and targeting it for
proteosomal degradation (Liao et al., 2004). Upon BAFF
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with the result that the amount of NIK gradually increases,
thereby promoting NF-kB2 processing (Liao et al., 2004).
Mice lacking B cell expression of TRAF3 have recently been
generated and display increased NF-kB2 activation as well as in-
creased B cell survival (Xie et al., 2007), suggesting that TRAF3
may act as a negative regulator of BAFF signaling in vivo. How-
ever, the mechanisms whereby TRAF3 mediates NIK degrada-
tion or is itself targeted for degradation are unclear because the
‘‘really interesting new gene’’ (RING) finger domain of TRAF3
does not display detectable ubiquitin ligase activity (Liao et al.,
2004). Although it is not directly recruited to BAFF-R, a role for
TRAF2 as well as TRAF3 in BAFF signaling has been suggested
by the increased NF-kB2 activation and survival exhibited by
primary B cells lacking expression of TRAF2 (Grech et al., 2004).
To clarify the roles of TRAF2 and TRAF3 in regulating the
survival of primary lymphocytes, we produced mice that lack
B cell or T cell expression of TRAF2 and/or TRAF3. According to
our results, TRAF2 and TRAF3 act cooperatively and nonredun-
dantly to suppress B cell but not T cell survival. BAFF-BAFF-R
signaling was shown to reverse TRAF2-TRAF3-mediated signal
repression during normal B cell development by inducing
TRAF2-mediated depletion of TRAF3. TRAF2 therefore plays
dual roles in determining BAFF-dependent nature of B cell devel-
opment, thereby underpinning the independent regulation of
B and T lymphocyte homeostasis.
RESULTS
Production of Traf3lox/lox Mice
To achieve lineage-specific inactivation of TRAF2 expression,we
previously produced mice carrying loxP sites homologously
recombined either side of the secondcoding exonofTraf2 (Grech
et al., 2004). A similar strategy was employed to produce mice
carrying a ‘‘floxed’’ version of Traf3 (see Figure S1 available on-
line). Gene targeting was performed with a C57BL/6 embryonic
stem (ES) cell line, and mice carrying the targeted Traf3 allele
were maintained on a C57BL/6 inbred background. Traf3lox/lox
mice, like Traf2lox/lox mice (Grech et al., 2004), were phenotypi-
cally normal and showed wild-type protein expression from the
targeted TRAF alleles in B cells and other cell types (Figure S2B).
TRAF2- and TRAF3-Deficient B Cells Exhibit
Identical Phenotypes
Mice with TRAF2-deficient B cells were generated previously by
crossing the type I interferon-inducibleMx1-CRE transgene onto
the Traf2lox/lox background (Traf2lox/loxMx1-CRE mice) (Grech
et al., 2004). Although this transgene does not direct CRE
expression specifically to B cells (Ku¨hn et al., 1995), TRAF2-
deficient B cells generated at low frequencies in these mice pro-
ceed to dominate the peripheral B cell pool because of their
extended lifespan (Grech et al., 2004). In the current study, inac-
tivation of TRAF2 or TRAF3 expression was achieved specifically
within B cells by producing Traf2lox/lox and Traf3lox/lox mice that
were also heterozygous for the Cd19-CRE allele (Rickert et al.,
1997). These mice were designated Traf2DB and Traf3DB,
respectively, and were verified by immunoblot analysis to have
extensive B cell-specific elimination of the corresponding
TRAF protein (Figure 1A).392 Immunity 28, 391–401, March 2008 ª2008 Elsevier Inc.As expected, the phenotype of Traf2DB mice resembled that
seen previously in Traf2lox/loxMx1-CRE mice (Grech et al.,
2004). Thus, compared to control animals, Traf2DB mice
contained greatly increased numbers of mature B cells, particu-
larly in the lymph node and splenic marginal zone (MZ) B cell
compartments (Figures 1B–1D). Upregulation of cell-surface
CD21 was also observed on B cells from Traf2DB mice
(Figure 1B). Analysis of Traf3DB mice revealed a phenotype
that was indistinguishable from that of Traf2DB animals. Thus,
not only did Traf3DB mice exhibit increased numbers of lymph
node and splenic MZ B cells as well as increased B cell expres-
sion of CD21, but the magnitude of these changes compared to
control animals reproduced those observed in Traf2DB mice
(Figures 1B–1D).
TRAF2- and TRAF3-Deficient B Cells Survive In Vitro
without Continued Exposure to BAFF
The increased B cell numbers and expansion of the MZ B cell
compartment in Traf2DB and Traf3DB mice resembled the
phenotypic changes observed previously in BAFF-transgenic
(BAFF-tg) mice that express supraphysiological amounts of
BAFF (Khare et al., 2000; Mackay et al., 1999). The convergence
of these phenotypes suggested that both TRAF2 and TRAF3
might act as negative regulators of BAFF-BAFF-R survival sig-
nals in B cells. To test this, the survival of Traf2DB and Traf3DB
B cells during ex vivo culture in unsupplemented medium was
measured. In the absence of the survival signals normally pro-
vided by BAFF in vivo, wild-type (control) B cells underwent rapid
cell death in vitro (Figure 2A). Similarly, BAFF-tg B cells, despite
their extended lifespan in vivo, remained dependent on BAFF
and also died rapidly in culture (Figure 2A). By contrast, approx-
imately half of the B cells from Traf2DB and Traf3DB mice re-
mained viable for up to 10 days when cultured in the absence
of BAFF (Figure 2A). Collectively, these data indicate that
TRAF2 and TRAF3 do inhibit the survival pathways normally ac-
tivated by BAFF. Indeed, the absence of either TRAF2 or TRAF3
from mature B cells allowed these survival pathways to remain
active without the requirement for ongoing exposure to BAFF.
B Cells Lacking either TRAF2 or TRAF3 Show Increased
Activation of the Alternative NF-kB Pathway
The signaling event triggered by BAFF-BAFF-R that is most
strongly associated with B cell survival is activation of the
alternative NF-kB pathway. As was previously observed in
Traf2lox/loxMx1-CRE mice (Grech et al., 2004), Traf2DB B cells
displayed increased processing of the p100 NF-kB2 protein to
p52 (Figure 2B). Comparable increases in cytoplasmic p100 pro-
cessing was observed in Traf3DB B cells, and both TRAF2- and
TRAF3-deficient B cells exhibited increased nuclear transloca-
tion of p52 as well as its binding partner RelB (Figure 2B). The
absence of either TRAF2 or TRAF3 in mature B cells, therefore,
resulted in hyperactivation of the alternative NF-kB pathway,
similar to that observed in BAFF-tg B cells (Figure 2B).
B Cells Lacking either TRAF2 or TRAF3 Share
a Common Gene-Expression Profile
The similar phenotypes exhibited by Traf2DB and Traf3DBmice
strongly suggested that TRAF2 and TRAF3 function coopera-
tively to regulate signaling and survival in mature B cells.
Immunity
TRAF2 and TRAF3 Control BAFF SignalingFigure 1. Efficient TRAF Inactivation and Increased B Cell Numbers in Traf2DB and Traf3DB Mice
(A) Lymph node B cells were purified from the indicated mouse lines and cytoplasmic lysates subjected to immunoblot analysis with antisera directed against the
indicated proteins.
(B) Flow cytometric analysis of lymph node cells from the indicated mouse lines. Data represent cells exhibiting a lymphocyte scatter profile and the window
indicates mature B cells.
(C) Flow cytometric analysis of spleen cells. Data are presented for total B cells (B220+ gate). Windows on the data show, from left to right: immature (CD21lo,
CD23lo), follicular (CD21int, CD23hi), and marginal zone (CD21hi, CD23lo) B cell populations.
In both (B) and (C), the numbers indicate the proportion of displayed events falling within the associated windows.
(D) Enumeration of lymphocytes from pooled lymph nodes and spleens of various mouse lines exhibiting the indicated lymphocyte phenotypes as determined by
flow cytometry. Points represent data from individual mice and bars indicate the arithmetic means.Immunity 28, 391–401, March 2008 ª2008 Elsevier Inc. 393According to this scenario, the removal of either TRAF2 or TRAF3
fromB cells would be expected to result in similar changes to the
overall gene-expression profile when compared to that of
wild-type B cells. To test this, gene microarray analysis was per-
formed on B cells purified from the lymph nodes of two Traf2DB,
two Traf3DB, and four control mice. This analysis identified 34
genes for which the mRNA expression in B cells from eitherTraf2DB or Traf3DBmice wasmore than 2-fold higher (27 genes)
or 2-fold lower (7 genes) compared to the amount expressed in
control B cells. Strikingly, every mRNA identified to be upregu-
lated or downregulated in TRAF2-deficient B cells was similarly
altered in TRAF3-deficient B cells, and vice versa (Figure 2C).
In other words, global analysis of mRNAs derived from more
than 39,000 different genes revealed that the absence of either
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effects on the overall gene-expression profile. Furthermore,
the majority of the mRNAs differentially expressed in both
Traf2DB and Traf3DB compared to control B cells were similarly
altered in lymph node B cells from BAFF-tg mice (Figure 2C).
Many of these genes therefore constitute normal targets of
BAFF signaling in B cells, consistent with the proposition that
TRAF2 and TRAF3 act cooperatively and nonredundantly as
negative regulators of signaling pathways normally activated
by BAFF.
Figure 2. Extended In Vitro Survival, Hyper-
activity of the Alternative NF-kB Pathway,
and Coincident Regulation of BAFF Target
Genes in B Cells from Traf2DB and Traf3DB
Mice
(A) Purified lymph node B cells from the indicated
mouse lines were incubated in unsupplemented
culture medium, and the number of live cells pres-
ent at the indicated time points was assayed by
flow cytometry. Points represent data from indi-
vidual mice and lines connect the means. Overlap-
ping data were obtained from the four control ge-
notypes (wild-type, Cd19-CRE+, Traf2lox/lox, and
Traf3lox/lox), and a single line was applied to these
data.
(B) Cytoplasmic and nuclear extracts from purified
lymph node B cells were subjected to immunoblot
analysis with antisera directed against the indi-
cated proteins. B-tg, BAFF-tg.
(C) Gene-expression analysis was performed on
sort-purified lymph node B cells prepared from
two Traf2DB mice, two Traf3DB mice, and four
control mice with an Affymetrix gene chip. Geno-
types of the control mice (from left to right): Tra-
f2lox/lox, Cd19-CRE+, Traf2lox/lox, and Traf3lox/lox.
Gene-expression data were normalized on a per
gene basis relative to the mean value obtained
from the control samples. Data are shown for
mRNAs whose expression in Traf2DB or Traf3DB
B cells was either more than 2-fold higher or less
than half of the mean value obtained from the con-
trols. Gene expression in lymph node B cells from
BAFF-tg compared to wild-type mice was ana-
lyzed and normalized separately.
were all similar in Traf2DB, Traf3DB, and
Traf2Traf3DB B cells (Figure 3A). In addi-
tion, removal of both TRAF2 and TRAF3
did not result in any further activation of
the alternative NF-kB pathway, because
the extent of p100 processing to p52
and nuclear translocation of p52 and RelB were comparable in
Traf2DB, Traf3DB, and Traf2Traf3DB B cells (Figure 3B). Like-
wise, B cells from all three types of mice showed similar BAFF-
independent survival in vitro (Figure 2A and data not shown).
When taken in conjunction with the gene-expression analysis
(Figure 2C), these results confirm that TRAF2 and TRAF3 each
play complementary and nonredundant roles in regulating spe-
cific pathways normally activated by BAFF signaling in mature
B cells.Inactivation of Both TRAF2 and TRAF3 Produces
No Further Alterations in B Cell Phenotype
Further support for the codependent roles of TRAF2 and TRAF3
in regulating B cell signaling and survival was obtained through
analysis of mice lacking expression of both TRAF2 and TRAF3
in their B cells (Traf2Traf3DB mice) (Figure S2C). Analysis of
thesemice revealed that the overall expansion of B cells in lymph
node and spleen, the specific expansion of splenic marginal
zone B cells, and upregulation of cell-surface CD21 on B cells394 Immunity 28, 391–401, March 2008 ª2008 Elsevier Inc.TRAF2- and TRAF3-Deficient T Cells
Do Not Show Extended Survival
The fundamental roles of TRAF2 and TRAF3 in regulating the
survival of primary B cells led us to investigate whether these
molecules might play a similar role in T cells. Two additional lines
of mice were produced in which TRAF2 or TRAF3 expression
was selectively eliminated from the T cell lineage. To do this,
an Lck-CRE transgene, which drives predominantly T cell-
restricted expression of CRE (Orban et al., 1992), was crossed
onto homozygous Traf2lox/lox and Traf3lox/lox backgrounds to
Immunity
TRAF2 and TRAF3 Control BAFF SignalingFigure 3. Traf2Traf3DBMice, Deficient in B
Cell Expression of TRAF2 and TRAF3, Ex-
hibit Expansion of Mature B Cells In Vivo
and Increased B Cell NF-kB2 Signaling
Similar to that in Traf2DB and Traf3DBMice
(A) FACS analysis of B cell populations from the
lymph node (top) and spleen (bottom) of mice of
the indicated genotypes were analyzed as for
Figure 1B.
(B) Nuclear and cytoplasmic lysates of B cells
purified from the lymph nodes of mice of the indi-
cated genotypes were subjected to immunoblot
analysis as for Figure 2C.
sors whose inhibitory activity must be
overcome by intracellular events trig-
gered by BAFF signaling. To distinguish
between these possibilities, we bred the
Traf2DB mice onto a BAFF-deficient
(Tnfsf13b/) background. If TRAF2-
TRAF3-mediated signal repression acts
downstream of BAFF-signaling, then the
elimination of TRAF2 expression would
be unable to rescue B cell development
in Tnfsf13b/ mice because no BAFF-
BAFF-R signaling could be initiated.
However, if TRAF2 and TRAF3 act as
constitutive repressors of the key path-
ways activated by BAFF signaling, then
the absence of TRAF2 should remove
the requirement for BAFF-BAFF-R signal-
ing and thus restore B cell development in
Tnfsf13b/ animals.
produce Traf2DT and Traf3DTmice, respectively (Figure S2B). In
contrast to the dramatic increase in mature B cell numbers ob-
served in Traf2DB and Traf3DB mice, Traf2DT and Traf3DT
mice contained normal or even reduced numbers of peripheral
CD4+ and CD8+ T cells (Figure 4A). In addition, T cells purified
ex vivo and cultured in unsupplemented medium in vitro were
found to die rapidly and with similar kinetics regardless of their
expression of TRAF2 or TRAF3 (Figure 4B). Importantly, T cells
from Traf2DT and Traf3DT mice did show extensive activation
of the alternative NF-kB pathway (Figure 4C). These results dem-
onstrate that although TRAF2 and TRAF3 suppress the alterna-
tive NF-kB pathway in both T and B cells, their suppression of
cellular survival pathways is specific for the B cell lineage.
BAFF Sustains B Cell Development by Reversing
the Constitutive Suppression of Survival Signals
Enforced by TRAF2 and TRAF3
The results documented thus far clearly demonstrated that
TRAF2 and TRAF3 cooperatively inhibit BAFF signaling path-
ways in mature B cells. However, the precise nature of this inhib-
itory function still remained to be determined. On the one hand,
TRAF2 and TRAF3 could be acting downstream of BAFF signal-
ing by dampening signals initiated by BAFF. Alternatively, their
modus operandi might be akin to that of the I-kB proteins (Bald-
win, 1996), with TRAF2 and TRAF3 acting as constitutive repres-The clear result obtained was that the development and sur-
vival of mature B cells in BAFF-deficient mice was completely
rescued by eliminating TRAF2 expression from the B cell lineage.
Thus, while mature B cells were virtually absent from BAFF-defi-
cient mice with normal TRAF2 expression (Tnfsf13b/Traf2lox/lox
mice), Tnfsf13b/Traf2DBmice contained large numbers ofma-
ture (AA4.1) lymph node B cells (Figure 5A) as well as both fol-
licular (CD21int, CD23hi) andmarginal zone (CD21hi, CD1dhi) phe-
notype B cells in the spleen (Figure 5B). These results
demonstrate that the cooperative action of TRAF2 and TRAF3
constitutively represses key survival and maturation pathways
that operate during normal B cell development. The requirement
for BAFF-BAFF-R signaling to sustain B cell development is
therefore due to its ability to reverse TRAF2-TRAF3-mediated
suppression of these pathways.
TRAF2 Mediates Extensive BAFF-BAFF-R-Dependent
Depletion of TRAF3 during B Cell Development
We next investigated the mechanism whereby BAFF-BAFF-R
signaling reverses the TRAF2-TRAF3-mediated suppression of
B cell survival and maturation pathways. Previous studies with
transformed B cell lines have indicated that BAFF signaling can
trigger proteolytic degradation of TRAF3 (Liao et al., 2004), which
would be predicted to reverse TRAF2-TRAF3-mediated signal
repression. This led us to examine whether BAFF-BAFF-RImmunity 28, 391–401, March 2008 ª2008 Elsevier Inc. 395
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TRAF2 and TRAF3 Control BAFF SignalingFigure 4. TRAF2- and TRAF3-Deficient T
Cells Do Not Accumulate or Survive Prefer-
entially Despite Displaying Spontaneous
Activation of the Alternative NF-kB Pathway
(A) Lymph nodes and spleens were obtained from
mice of the indicated genotypes and total num-
bers of CD4+ and CD8+ T cells assessed by flow
cytometry. Points represent data from individual
mice and bars show the arithmetic means.
(B) Purified lymph node T cells from the indicated
mouse lines were incubated in unsupplemented
culture medium and the number of live cells pres-
ent at the indicated time points assayed by flow
cytometry. Points represent data from individual
mice and lines connect the means. Overlapping
data were obtained from the two control geno-
types (Traf2lox/lox and Traf3lox/lox) and a single line
applied to these data.
(C) Lymph node T cells were purified from the indi-
cated mouse lines and cytoplasmic and nuclear
extracts prepared and subjected to immunoblot
analysis with antisera directed against the indi-
cated proteins.signaling triggers TRAF3 degradation during the development of
normal primary B cells and, if so, how TRAF2might be involved in
this process.396 Immunity 28, 391–401, March 2008 ª2008 Elsevier Inc.Two independent observations indicated that the binding of
BAFF to BAFF-R during normal B cell development results in
the depletion of cellular TRAF3. First, the amount of TRAF3Figure 5. Absence of TRAF2 Expression in
the B Cell Lineage Facilitates BAFF-Inde-
pendent B Cell Development and Survival
In Vivo
Traf2lox/lox and Traf2DB mice were crossed onto
a BAFF-deficient (Tnfsf13b/) background. Flow
cytometric analysis of lymph node (A) or spleen
(B) was carried out as for Figure 1B. Data in
B220 versus AA4.1 profiles are from cells falling
within the lymphocyte scatter gate. Windows indi-
cate immature (B220+, AA4.1+) and mature
(B220+, AA4.1) phenotype B cells. Data in CD21
versus CD23 and CD21 versus CD1d profiles are
from total B cells (B220+ gate) and windows
show follicular (CD21int, CD23hi) and marginal
zone (CD21hi, CD23lo and CD21hi, CD1dhi) pheno-
type B cells. Numbers indicate the proportion
of displayed events falling within the associated
windows.
Immunity
TRAF2 and TRAF3 Control BAFF Signalingprotein is drastically reduced as B cells mature from their B220+,
IgM bone-marrow precursors in vivo (Figure 6A). This observa-
tion is consistent with BAFF-R mediating this process because
this receptor is not expressed until after B lineage cells com-
mence B cell antigen receptor (BCR) expression (Hsu et al.,
2002). Second, immature (AA4.1+) splenic B cells contain large
amounts of TRAF3 protein in both BAFF-deficient (Tnfsf13b/)
and BAFF-R-deficient (Tnfrsf13c/) compared to wild-type
mice (Figure 6B). In each of these cases, the changes in expres-
sion of TRAF3 protein did not result from alterations in the
amount of Traf3 mRNA (Figure S3) and correlated with the acti-
vation of p100 processing (Figures 6A and 6B). These data indi-
cate that BAFF signaling through BAFF-R triggers extensive
post-transcriptional downregulation of TRAF3 protein during B
cell development in vivo, most likely by targeting it for proteolytic
degradation. B cells from TACI-deficient (Tnfrsf13b/) and
wild-type mice were found to contain similar amounts of
TRAF3 protein (Figure S4), confirming that BAFF-R is the only
Figure 6. TRAF3 Is Downregulated in a TRAF2-Dependent Manner
by BAFF-BAFF-R Signaling during B Cell Development
(A) Precursor B cells (PreB = B220+, IgM) and mature B cells (MatB = B220+,
CD23hi, IgDhi) were sorted from wild-type bone marrow and whole-cell lysates
subjected to immunoblot analysis. Note the extensive downregulation of
TRAF3 and activation of p100 processing during B cell development.
(B) Immature B220+, AA4.1+ B cells (see Figure 5) were sorted from the spleens
of the indicated mice. Whole-cell lysates were obtained and subjected to im-
munoblot analysis. Note that TRAF3 downregulation and p100 processing re-
quire the expression of both BAFF and BAFF-R.
(C) Lymph node B cells (left) or T cells (right) were purified from mice of the in-
dicated genotypes and cytoplasmic lysates subjected to immunoblot analysis.
Note that control B cells express low amounts of TRAF3 compared to T cells
and TRAF2-deficient B cells. b-actin was used as a loading control in all cases.BAFF-binding receptor required to trigger TRAF3 depletion
during B cell development.
To determine the involvement of TRAF2 in the depletion of
TRAF3 in B cells by BAFF-BAFF-R signaling, we examined the
amount of TRAF3 protein present in TRAF2-deficient B cells.
According to our previous data, TRAF2-deficient B cells from
Traf2lox/loxMx1-CRE mice contain greatly increased amounts of
TRAF3 compared to control B cells (Grech et al., 2004). This phe-
nomenon was also observed in the TRAF2-deficient B cells
isolated from Traf2DBmice (Figure 1A) and was not due to upre-
gulation of Traf3 mRNA (Figure S3). This finding cannot be
explained by the modest increase in mature (AA4.1) phenotype
cells among the lymph node B cells from Traf2DB mice
(Figure 5A) becausemature and immature peripheral B cells con-
tain similarly low amounts of TRAF3 (Figures 6A and 6B). It
appears, therefore, that the extensive BAFF-BAFF-R-mediated
depletion of TRAF3 protein that occurs during B cell develop-
ment (Figures 6A and 6B) requires the presence of TRAF2.
This conclusion was confirmed by additional analysis of the
expression of TRAF3 in wild-type and TRAF2-deficient T cells.
Normal naive T cells do not undergo BAFF-BAFF-R signaling,
as indicated by the absence of p100 processing (Figure 4C).
Because T cells and B cells express similar amounts of Traf3
mRNA (Figure S3), T cells would be expected to contain more
TRAF3 protein than wild-type B cells but similar amounts to
those in B cells in which post-transcriptional depletion of
TRAF3 has been inactivated. The amount of TRAF3 in wild-
type T cells were indeed found to be much greater than those
in wild-type B cells, whereas they were virtually identical to those
present in TRAF2-deficient B cells (Figure 6C). Furthermore, the
amount of TRAF3 protein was unchanged in TRAF2-deficient
compared to wild-type T cells (Figure 6C), a finding consistent
with the dependence of TRAF2-mediated depletion of TRAF3
on upstream signals from BAFF-R. In summary, therefore,
BAFF-BAFF-R signaling reverses the TRAF2-TRAF3-mediated
suppression of survival pathways during in vivo B cell develop-
ment by triggering post-transcriptional depletion of TRAF3
protein via a process that is completely dependent on the
expression of TRAF2 (Figure S5).
DISCUSSION
The specific effects of TRAF2 and TRAF3 deficiency on B cell
phenotype and gene expression documented here indicated
that these molecules act by inhibiting signaling pathways nor-
mally activated by the obligatory B cell survival factor BAFF.
This was further illustrated by the finding that elimination of
TRAF2-TRAF3-mediated signal repression completely removed
the dependence of B cells on BAFF for their development, mat-
uration, and survival in vivo. This striking result also demon-
strated that, rather than simply dampening signals initiated by
BAFF, TRAF2 and TRAF3 act cooperatively to constitutively
suppress these key survival and maturation pathways. The re-
quirement for BAFF-BAFF-R signaling to sustain B cell develop-
ment and homeostasis is therefore based on its ability to reverse
the TRAF2-TRAF3-mediated suppression of B cell survival.
In contrast to the profound effects observed in B cells, the
removal of either TRAF2 or TRAF3 expression from T cell lineage
did not increase the survival of mature T cells. TRAF2- andImmunity 28, 391–401, March 2008 ª2008 Elsevier Inc. 397
Immunity
TRAF2 and TRAF3 Control BAFF SignalingTRAF3-deficient T cells did nevertheless exhibit extensive
NF-kB2 activation. The constitutive suppression of the alterna-
tive NF-kB pathway by TRAF2 and TRAF3 therefore appears to
be universal, whereas their ability to suppress lymphocyte sur-
vival is restricted to the B cell lineage. The precise reasons for
this dichotomy are unclear but presumably reflect the distinct
intracellular milieu present in B and T lymphocytes. In the context
of the mature B cell, therefore, pathways repressed by TRAF2
and TRAF3 (and activated by BAFF) complement BCR-mediated
signals to sustainmature B cell survival. On the other hand, these
pathways are either not activated or do not complement
TCR-mediated survival signals in mature T cells. Instead, signals
delivered via interleukin-7 receptor provide critical survival stim-
uli in the context of the mature T cell (Schluns et al., 2000; Tan
et al., 2001). The differential activity of TRAF2 and TRAF3 in
regulating B versus T cell survival therefore underpins the inde-
pendent regulation of homeostasis in these two lymphocyte
populations.
A key observation in this study was that the amount of TRAF3
protein in TRAF2-deficient B cells was greatly increased com-
pared to control B cells. This result seems paradoxical: B cells
with either no TRAF3 (Traf3DB) or with large amounts of
TRAF3 (Traf2DB) exhibit the same phenotype. What it empha-
sizes, however, is that the repression of signaling enforced by
TRAF2 and TRAF3 occurs cooperatively and is absolutely reliant
on the presence of both proteins. The accumulation of TRAF3 in
TRAF2-deficient B cells was in fact found to be due to prevention
of the normal depletion of TRAF3 that occurs during the develop-
ment of wild-type B cells. The fact that this depletion of TRAF3
requires BAFF signaling through BAFF-R as well as the presence
of TRAF2 establishes a dual role for TRAF2 in BAFF signaling.
Thus, TRAF2 not only mediates the suppression of B cell survival
signals in conjunction with TRAF3 but is also required for the
depletion of TRAF3 that allows BAFF-BAFF-R signaling to sus-
tain B cell development.
Based on these data, we propose the following model for the
regulation ofmature B cell development by BAFF. In the absence
of BAFF, TRAF2 and TRAF3 act cooperatively to repress the sur-
vival of mature B cells by suppressing NF-kB2 activation and
possibly other prosurvival pathways. In wild-type mice, B cells
express BAFF-R and bind BAFF soon after initial expression of
antigen receptor. TRAF3 is subsequently recruited to BAFF-R
and then depleted from the cell by a TRAF2-dependent process,
possibly involving targeting to the proteosome by the TRAF2-
associated ubiquitin ligase c-IAP1 (Li et al., 2002). Depletion of
TRAF3 lifts repression of NF-kB2 and/or other prosurvival
pathways, thereby facilitating B cell survival. This depletion of
TRAF3 by BAFF-R is analogous to the degradation of I-kB
repressor proteins induced by other receptors that leads to acti-
vation of the canonical NF-kB pathway (Baldwin, 1996). Key
survival pathways are constitutively active in the absence of
TRAF3, with the result that B cells genetically deficient in
TRAF3 no longer require BAFF in order to survive. TRAF2-defi-
cient B cells lack the capacity to deplete TRAF3 but also survive
independently of BAFF because of the requirement for TRAF2 as
well as TRAF3 to suppress B cell survival. Naive T cells do not
receive signals through BAFF-R nor any other receptor that
promotes TRAF2-dependent TRAF3 degradation, with the result
that the NF-kB2 pathway is inactive in these cells. Thus, in398 Immunity 28, 391–401, March 2008 ª2008 Elsevier Inc.contrast to B cells, naive T cells survive irrespective of TRAF2
or TRAF3 expression because of signals delivered via the inter-
leukin-7 receptor.
Several questions remain to be answered before it can be
precisely determined how TRAF2 and TRAF3 control B cell sur-
vival. First, how does TRAF2 target TRAF3 for BAFF-mediated
degradation when it is not directly recruited to BAFF-R? NIK
binds TRAF2 and TRAF3 (Liao et al., 2004; Malinin et al., 1997),
raising the possibility that it facilitates TRAF2-mediated deple-
tion of TRAF3 after BAFF-R stimulation. This possibility is sup-
ported by the recent observation that TRAF3 protein is present
in increased amounts in primary B cells overexpressing amutant
NIK protein that lacks TRAF3-binding activity and which would
therefore fail to colocalize TRAF2 and TRAF3 (M. Schmidt-
Supprian, personal communication). These studies also confirm
that increased expression of NIK in primary B cells, especially the
non-TRAF3 binding mutant, results in expansion of the B cell
compartment and extended B cell survival similar to Traf2DB
and Traf3DBmice (M. Schmidt-Supprian, personal communica-
tion). It is likely, therefore, that the suppression of signaling
mediated by TRAF2 and TRAF3 occurs via their common inter-
action with NIK. Because TRAF3 acts by targeting NIK for pro-
teolytic degradation (Liao et al., 2004), the requirement for
TRAF2 and TRAF3 to suppress NF-kB2 activation may reflect
a role for TRAF2 in the degradation of NIK as well as TRAF3. It
would therefore be predicted that both TRAF2- and TRAF3-
deficient B cells should contain increased amounts of NIK pro-
tein. However, we (data not shown) and others (Xie et al., 2007;
M. Schmidt-Supprian, personal communication) have been
unable to quantify NIK in primary B cells because of the low
amounts of NIK protein in this cell type.
Recently published studies support the scenario described
above and indicate that the c-IAP proteins are likely to play
a key role. Thus, TRAF2-deficient fibroblasts not only have
extensive NF-kB2 activation but also have greatly increased
amounts of NIK (Vince et al., 2007). c-IAP1-deficient fibroblasts
showed a very similar phenotype (Vince et al., 2007), suggesting
that TRAF2 may mediate NIK degradation by recruiting the ubiq-
uitin ligase activity of c-IAP1 to NIK. Consistent with this, c-IAP1-
mediated ubiquitination and degradation of NIK requires the
TRAF2-binding site of c-IAP1 (Varfolomeev et al., 2007). It is
not clear why the binding of TRAF3 to NIK is also required for
this process. TRAF2- and TRAF3-deficient B cells showed
normal expression of c-IAP1 (data not shown), indicating that
the constitutive activation of the NF-kB2 pathway in these cells
is not due to increased expression of c-IAP1 but presumably
to modulation of its ability to mediate NIK ubiquitination.
Given the prominent activation of the alternative NF-kB path-
way in TRAF2- and TRAF3-deficient B cells, it was surprising
that the genes that were upregulated greater than 2-fold in these
cells did not include obvious NF-kB targets. However, target
genes of the alternative NF-kB pathway are not well character-
ized andmay in fact include some of these genes. The enhanced
BAFF-independent survival of Traf2DB and Traf3DB B cells
points to a possible role for some of these genes in formation
of B cell lineage tumors. Indeed, our results posit that Traf2
and Traf3 may act as tumor-suppressor genes in the B cell line-
age. In support of this, recent analyses have revealed that muta-
tion of TRAF3 is a common genetic lesion in human multiple
Immunity
TRAF2 and TRAF3 Control BAFF Signalingmyeloma (Annunziata et al., 2007; Keats et al., 2007). Moreover,
mutations in the genes encoding TRAF2 and TRAF3 may also
potentiate autoantibody production and autoimmunity in view
of the established role of excessive BAFF signaling in compro-
mising B cell self-tolerance (Lesley et al., 2004; Thien et al.,
2004). Traf2DB and Traf3DB mice may therefore provide new




Conditionally TRAF2-deficient (Traf2lox/lox) mice (Grech et al., 2004) as well as
Cd19-CRE transgenic (Rickert et al., 1997), Lck-CRE transgenic (Orban et al.,
1992), BAFF-transgenic (Mackay et al., 1999), Tnfsf13b/ (Schiemann et al.,
2001), and Tnfrsf13c/ (Sasaki et al., 2004) mice have all been previously
described. The production of Traf3lox/lox mice is described in detail in Supple-
mental Data. Mice were screened by PCR analysis of blood or tail-tip DNA. All
mice weremaintained on an inbred C57BL/6 genetic background at the animal
facilities of the Centenary and Garvan Institutes and analyzed between 2 and 6
months of age. All animal experiments were carried under protocols approved
by the University of Sydney and Garvan Institute/St. Vincent’s Hospital Animal
Ethics Committees.
Flow Cytometry
Flow cytometric analysis was performed on a FacsCanto flow cytometer (BD
Biosciences) with FacsDiva software (BDBiosciences) and analysis performed
with FlowJo (TreeStar). Single-cell suspensions were prepared from spleens
and lymph nodes (pooled cervical, inguinal, axillary, brachial, and mesenteric
nodes) and stained and analyzed as previously described (Grech et al., 2004).
The following antibodies and conjugates were purchased from BD Biosci-
ences: anti-CD16 (2.4G2), anti-B220-FITC, -PE, -PerCP, -APC (RA3-6B2),
anti-CD21-FITC (7G6), anti-CD23-PE (B3B4), anti-CD1d-biotin (1B1), anti-
CD4-FITC (L3T4), anti-CD8-PE (53-6.7), and streptavidin-PerCP. The following
antibody was purchased from eBiosciences: anti-C1qRp-APC (AA4.1). Light
scatter gating was performed on all samples to include lymphocytes but
exclude doublets, dead cells, and debris.
Lysate Preparation
B and T cells were purified from lymph nodes with Mouse B Cell Isolation Kit
and Mouse T Cell Isolation Kit (Miltenyi Biotec), respectively, as per manufac-
turer’s instructions. Labeled cells were separated with AutoMacs Separator
(Miltenyi Biotec) and negative fraction collected, counted, and washed in
PBS. Nuclear and cytoplasmic lysates were prepared with NE-PER Nuclear
and Cytoplasmic Extraction Kit (Pierce) as per manufacturer’s instructions,
with the addition of 100 mg/ml AEBSF (Roche), 10 mg/ml leupeptin, 1 mM
sodium pervanadate, and 10mMsodium fluoride (all Sigma Aldrich). Precursor
B cells (B220+, IgM) andmature B cells (B220+, CD23hi, IgDhi) from bonemar-
row, as well as immature splenic B cells (B220+, AA4.1+) were isolated by cell
sorting on FacsVantage or FacsAria cell sorters (BD Biosciences). Whole-cell
lysates were prepared with RIPA buffer (25 mM HEPES, 250 mM NaCl, 2 mM
EDTA, 0.5% sodium deoxycholate, 0.1% SDS, 1% NP-40, 100 mg/ml AEBSF,
10 mg/ml leupeptin, 1 mM sodium pervanadate, and 10 mM sodium fluoride).
Immunoblotting
All lysates were subjected to polyacrylamide gel electrophoresis on 4%–12%
gradient NuPAGE Bis-Tris gels (Invitrogen) in XCell SureLock Mini-Cell
apparatus (Invitrogen) and transferred onto Immobilon-P PVDF membranes
(Millipore) with XCell IITM Blot module (Invitrogen). Membranes were blocked
and antibodies diluted in 5% BSA/0.2% Tween20/Tris-buffered saline. The
following antibodies were purchased from Santa Cruz: anti-TRAF3 (H122),
anti-TRAF2 (C20), anti-RelB (C19), anti-USF2 (C20), anti-rabbit IgG-HRP
(sc-2030), anti-mouse IgG-HRP (sc2031). Anti-NFkB2 (4882) was purchased
from Cell Signaling Technologies and anti-b-actin (AC15) from Sigma Aldrich.Microarray Experiments
RNA was extracted from cell-sort-purified follicular B cells from the lymph
nodes of mice with RNeasy Mini Kit (QIAGEN) as per manufacturer’s instruc-
tions. RNA was quantitated on a RNA 6000 Nano Chip (Agilent) with 2100
Bioanalyser (Agilent). RNA was then amplified with the GeneChip Two-cycle
Target Labeling andControl Kit (Affymetrix) as permanufacturer’s instructions.
Resulting cRNA was hybridized to Mouse Genome 430 2.0 Arrays (Affymetrix),
washed, and stained on GeneChip Fluidics Station 400 (Affymetrix) and
scanned with a GeneChip Scanner (Affymetrix). Analysis of data was per-
formed with GeneSpring software (Agilent). All samples were normalized on
a per gene basis to the median of the control samples run at the same time.
Traf2DB and Traf3DB samples were individually compared to the median of
their respective controls. Genes were considered 2-fold upregulated only if
duplicate samples agreed and raw signals of the TRAF-deficient samples
were greater than 50. Genes were considered 2-fold downregulated only if
duplicate samples agreed and raw signals of the controls were greater than
50. Genes were excluded if the normalized signal for all controls did not fall
between 0.5 and 1.5. For genes identified as differentially regulated bymultiple
independent probes (Chka, Adm, Gpr43, Siat8f, Socs3, AI449310, Tsc22d1),
results shown are for the probe with the highest signal intensity. Gene labels
used are those prescribed by the Mouse Genomic Nomenclature Committee
(MGNC).
In Vitro Survival Assays
B and T cells were purified from lymph nodes with Mouse B Cell Isolation Kit
and Mouse T Cell Isolation Kit (Miltenyi Biotec), respectively, as per manufac-
turer’s instructions. Labeled cells were separated with AutoMacs Separator
(Miltenyi Biotec) and negative fraction collected, counted, and resuspended
at 106 cells/mL in RPMI supplemented with 10% FCS, 55 mM b-mercaptoetha-
nol, 1 mM sodium pyruvate, 0.1 M nonessential amino acids, 10 mM HEPES,
50 units/ml penicillin, 50 mg/ml streptomycin. Cells were cultured at 106 cells
per well in 24-well plates (BD Biosciences). 23 105 Calibrite beads (BD Biosci-
ences) were added to each well prior to harvesting and staining for flow cytom-
etry. A known number of beads were collected and the corresponding number
of events falling within a live lymphocyte gate, using forward and side light
scatter, was used to calculate the total number of live cells in each well. Cell
numbers were then expressed as a percentage of the live cells present in
the corresponding wells on Day 0.
ACCESSION NUMBERS
The complete data set has been submitted to the GEO database under
accession #GSE10422.
SUPPLEMENTAL DATA
Five figures and Experimental Procedures are available at http://www.
immunity.com/cgi/content/full/28/3/391/DC1/.
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